1. Home
  2. DBD vs XNCR Comparison

DBD vs XNCR Comparison

Compare DBD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diebold Nixdorf Incorporated

DBD

Diebold Nixdorf Incorporated

N/A

Current Price

$52.02

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Logo Xencor Inc.

XNCR

Xencor Inc.

N/A

Current Price

$33.57

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DBD
XNCR
Founded
1859
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
DBD
XNCR
Price
$52.02
$33.57
Analyst Decision
Strong Buy
Buy
Analyst Count
3
14
Target Price
★ $85.00
$43.83
AVG Volume (30 Days)
343.9K
★ 1.5M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 677.27
65.36
EPS
★ 0.77
N/A
Revenue
★ $3,805,700,000.00
$125,576,000.00
Revenue This Year
$1.93
$58.19
Revenue Next Year
$2.54
N/A
P/E Ratio
$65.29
★ N/A
Revenue Growth
1.46
★ 13.65
52 Week Low
$49.77
$10.38
52 Week High
$92.09
$40.60

Technical Indicators

Market Signals
Indicator
DBD
XNCR
Relative Strength Index (RSI) 32.61 54.03
Support Level N/A $22.80
Resistance Level $85.54 $33.60
Average True Range (ATR) 2.43 2.08
MACD -0.50 -0.54
Stochastic Oscillator 18.84 35.21

Price Performance

Historical Comparison
DBD
XNCR

About DBD Diebold Nixdorf Incorporated

Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.

About XNCR Xencor Inc.

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

Share on Social Networks: